LISA RAHAIM: Open Payments
NPI 1982703914 · WOODBURY, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,082 in 64 payments from 14 companies in 2025. Trend: 2023 $1,607 · 2024 $1,174 · 2025 $1,082
Food & beverage: $1,082
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $196 |
| Regeneron Healthcare Solutions, Inc. | 8 | $152 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 10 | $152 |
| Janssen Biotech, Inc. | 5 | $94 |
| Phathom Pharmaceuticals, Inc. | 6 | $85 |
| Lilly USA, LLC | 4 | $83 |
| Gilead Sciences, Inc. | 5 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $58 |
| Madrigal Pharmaceuticals | 3 | $53 |
| Ardelyx, Inc. | 2 | $42 |
Products named: DUPIXENT, RINVOQ, XIFAXAN, TREMFYA, VOQUEZNA, OMVOH, ENTYVIO, REZDIFFRA.
Industry payments across NJ — which companies pay providers there.
